SCHEMBL5573282

SCHEMBL5573282

CC(C)(C)OC(=O)NC1=NC(=O)C(=Cc2ccc3ncccc3n2)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
METAP1 P53582 1/20 0.34
MAPK10 P53779 1/20 0.34
POLB P06746 1/20 0.34
BCHE P06276 1/20 0.33
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
NAMPT P43490 1/20 0.32
LCK P06239 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5628678 1.00 KDM4E (0.35) KDM4EL3MBTL1TDP1METAP1MAPK10
SCHEMBL5570147 0.87 MEN1 (0.40) KDM4EPOLBRAB9ANPC1MEN1
SCHEMBL5570149 0.87 MEN1 (0.40) KDM4EPOLBRAB9ANPC1MEN1
SCHEMBL14422269 0.80 GSK3B (0.42) RAB9ANPC1ALDH1A1HPGD
SCHEMBL5570139 0.78 METAP1 (0.36) KDM4EL3MBTL1TDP1METAP1POLB
SCHEMBL5570142 0.78 METAP1 (0.36) KDM4EL3MBTL1TDP1METAP1POLB
SCHEMBL27683833 0.78 ALDH1A1 (0.33) KDM4ERAB9ANPC1GAAHTT
SCHEMBL14422270 0.77 RAB9A (0.42) KDM4ETDP1POLBRAB9ANPC1
SCHEMBL5571316 0.75 PIM1 (0.34) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL5573752 0.74 APP (0.36) KDM4EL3MBTL1TDP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084673-A1 1,5-naphthyridine azolinone LIU JIN-JUN 2006-04-20 US claimed
US-7268231-B2 1,5-Naphthyridine azolinone HOFFMANN-LA ROCHE INC. (US) 2007-09-11 US disclosed
EP-1805174-A1 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2007-07-11 EP disclosed
WO-2006040052-A1 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2006-04-20 WO disclosed
US-20060084673-A1 1,5-naphthyridine azolinone LIU JIN-JUN 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084673-A1 1,5-naphthyridine azolinone CDK1, CDK15, CDK14 KDM4E 1444/4885L3MBTL1 2798/4885TDP1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.